Live
- Concerns Over NASA Astronaut Sunita Williams' Health After Recent Photos Show Significant Weight Loss
- Chandrababu holds meeting with ministers, discusses on SC Classification
- National anti-terror policy, strategy to be unveiled soon: HM Shah
- Donald Trump Effect: Gold Prices Drop Sharply in a Single Day
- Australian govt to ban social media access for children younger than 16
- ED conducts raids on multiple sellers linked to e-com players including Amazon, Flipkart
- India A vs Australia A: Contrasting outings for KL Rahul and Dhruv Jurel at Melbourne
- Lakshya and Ananya Panday Pair Up in Dharma Productions' Next Big Film
- After political furore, BJP leader withdraws slur on Sharad Pawar
- Kerala Cong cries foul over police raid on hotel rooms of women leaders, moves ECI
Dr Reddy's gets 8 observations from FDA
The US health regulator has issued eight observations to Dr Reddy's Laboratories after the inspection of its Duvvada facility in Andhra Pradesh, the pharma major said on Tuesday.
Hyderabad: The US health regulator has issued eight observations to Dr Reddy's Laboratories after the inspection of its Duvvada facility in Andhra Pradesh, the pharma major said on Tuesday.
The audit of the company's formulations manufacturing plant (Vizag SEZ Plant 1) at Duvvada, Visakhapatnam by the United States Food and Drug Administration (USFDA) completed on Tuesday, Dr Reddy's said in a filing to the BSE.
"We have been issued a Form 483 with 8 observations", it added. The company will address them comprehensively within the stipulated timeline, Dr Reddy's said.
As per the US health regulator," an FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts."
The FDA Form 483 notifies the company's management of objectionable conditions.
Meanwhile, the company has launched generic anti-epileptic Vigabatrin powder for oral solution in the US market.
The product is a generic version of Lundbeck's Sabril powder for oral solution, Dr Reddy's said.
